Vallabh Janardhan: Vascular Disease Is Sltimately A Story of Thrombosis
Vallabh Janardhan, Co-Founder and CMO at Insera Therapeutics, Inc., shared on LinkedIn:
”Dallas CV Updates 2026 reinforced something I’ve been thinking about increasingly: vascular disease is ultimately a story of thrombosis.
From coronary plaque rupture to embolic stroke to venous thromboembolism, the final common pathway is clot biology.
A particularly compelling discussion this year centered on Lipoprotein(a) by Dr. Shahzeb Khan — not only as an atherogenic particle, but as a pro-thrombotic contributor that may amplify clot formation across vascular beds.
As our understanding deepens, prevention and intervention are no longer separate conversations.
Credit to Dr. Srini Potluri and Dr. Robert Smith for convening a forum that blends clinical excellence with forward-looking discussion at Baylor Scott and White The Heart Hospital.
Always energizing to engage with colleagues shaping the next phase of cardiovascular care in Dallas and beyond.”
Stay updated with Hemostasis Today.
-
Feb 22, 2026, 07:20Leonardo Cardoso: Mechanical Thrombectomy Improves Functional Independence, Outcomes and Reduces Mortality
-
Feb 22, 2026, 07:08Ashkan Shoamanesh: OCEANIC-STROKE Focus on Stroke Subtypes and Response to Asundexian at ISC26
-
Feb 22, 2026, 06:43Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?
-
Feb 22, 2026, 06:32Priyansh Shah: Integrating Food-Based Nutrition Interventions Into Health Care Delivery
-
Feb 22, 2026, 06:18Thomas Reiser: How Can Medical and Healthcare Associations Stay Impactful in a Changing Environment?
-
Feb 22, 2026, 05:58Mark Crowther: Why Leaders Must Model What They Expect
-
Feb 21, 2026, 15:58Addressing Underdiagnosis and Care Inequities in Women and Girls with Bleeding Disorders – WFH
-
Feb 21, 2026, 15:49Sheharyar Raza: The Leaky Pipeline of AI and Machine Learning in Transfusion Medicine
-
Feb 21, 2026, 15:21Joanna Sadowska: Watching a Stem Cell Divide Reveals Life’s Blueprint